Skip to content
2000
Volume 8, Issue 12
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Farnesyl protein transferase (FPT) inhibition is an interesting and promising approach to non-cytotoxic anticancer therapy. Research in this area has resulted in several orally active compounds that are currently in clinical evaluation. This review focuses on FPT inhibitors in clinical trials and concentrates on the benzocycloheptapyridine class, with details on the discovery and development of SCH 66336, currently in Phase II clinical trials.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867013372021
2001-10-01
2025-05-07
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867013372021
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test